Clinical Trial Update: Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial of quizartinib in AML patients with FLT3-ITD mutation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED | Results posted: 2020-02-17